Regeneron Oncology Setback Delivered By US FDA Crackdown On Accelerated Approval

Odronextamab Was Filed For FL And DLBCL

 
• By Jessica Merrill
no
FDA rejected Regeneron's BLAs for odronextamab • Source: Shutterstock

More from Clinical Trials

More from R&D